Pembrolizumab berahyaluronidase alfa vs Tislelizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Pembrolizumab berahyaluronidase alfa · Keytruda Qlex

Marketed by Merck & Co.

Approved in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT05722015 · Phase 3 · active, not recruiting

Patients were randomised to the subcutaneous or intravenous form with a prespecified non-inferiority margin, and both primary pharmacokinetic comparisons passed that margin. The primary endpoints are drug blood levels rather than tumour control or survival, and the study was open-label, so it shows comparable exposure but does not by itself show clinical benefit.

Next expected readout: December 2029 · NCT07190248 (registry estimate)

Reported efficacy

Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)); Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State (Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)): Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose (Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)): Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy 1633.24 μg·day/mL (Geometric Coefficient of Variation 40.41) | Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy 1437.58 μg·day/mL (Geometric Coefficient of Variation 26.23) (met)

Result source: NCT05722015

Tislelizumab

Marketed by BeOne Medicines and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03358875 · Phase 3 · completed

The 805-participant trial was randomized and actively controlled with docetaxel, and its co-primary clinical endpoint of overall survival was met in both the full population and the PD-L1-positive subgroup. However, treatment assignment was not blinded, so despite the large sample and statistically significant survival results, the evidence is rated moderate rather than strong.

Next expected readout: November 2026 · NCT06704620 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPembrolizumab berahyaluronidase alfaTislelizumab
PFS, median—Trial running · NCT057220157.6 vs 5.5vs Paclitaxel + Carboplatinn 120NCT03594747
5 other results
OS, median—Trial running · NCT0572201526.1 vs 19.4vs Paclitaxel + Carboplatinn 120NCT03594747
1 other result
ORR64.3% vs 18.2%vs Pembrolizumabn 28NCT0621275274.2% vs 47.9%vs Paclitaxel + Carboplatinn 120NCT03594747
3 other results
  • 73.9% vs 47.9% n 119 · Phase 3 · secondary NCT03594747
  • 70% vs 49.6% n 120 · Phase 3 · secondary NCT03594747
  • 78.2% vs 49.6% n 119 · Phase 3 · secondary NCT03594747
Duration of response, median—Trial running · NCT057220158.4 vs 4.3vs Paclitaxel + Carboplatinn 89NCT03594747
3 other results

PFS, median

Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
Tislelizumab
7.6 vs 5.5vs Paclitaxel + Carboplatinn 120NCT03594747
5 other results

OS, median

Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
Tislelizumab
26.1 vs 19.4vs Paclitaxel + Carboplatinn 120NCT03594747
1 other result

ORR

Pembrolizumab berahyaluronidase alfa
64.3% vs 18.2%vs Pembrolizumabn 28NCT06212752
Tislelizumab
74.2% vs 47.9%vs Paclitaxel + Carboplatinn 120NCT03594747
3 other results
  • 73.9% vs 47.9% n 119 · Phase 3 · secondary NCT03594747
  • 70% vs 49.6% n 120 · Phase 3 · secondary NCT03594747
  • 78.2% vs 49.6% n 119 · Phase 3 · secondary NCT03594747

Duration of response, median

Pembrolizumab berahyaluronidase alfa
—Trial running · NCT05722015
Tislelizumab
8.4 vs 4.3vs Paclitaxel + Carboplatinn 89NCT03594747
3 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Pembrolizumab berahyaluronidase alfa: 2 of 4 rows · Tislelizumab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPembrolizumab berahyaluronidase alfaTislelizumab
Dropout rate
n/a: no completion milestonea
NCT05722015 · Phase 3 · combination
show 1 more result
n/a: no completion milestone
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestoneTislelizumab + Nab-paclitaxel + Cab
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
n/a: no completion milestoneTislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT05722015 · Phase 3 · combination
show 1 more result
—
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—Tislelizumab + Nab-paclitaxel + Cab
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
—Tislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Serious AEs
39%a
NCT05722015 · Phase 3 · combination
show 1 more result
42.9%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
46.6%Tislelizumab + Nab-paclitaxel + Cab
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
46.7%Tislelizumab + Paclitaxel + Carbop
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Most frequent reported AEs
a
anaemia 58.2%
neutropenia 41.8%
leukopenia 29.5%
NCT05722015 · Phase 3 · combination
show 1 more result
neutropenia 46.4%
anaemia 42.9%
constipation 39.3%
NCT06212752 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
b
anaemia 94.1%
alopecia 69.5%
neutrophil count decreased 61.9%
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
anaemia 89.2%
alopecia 65%
neutrophil count decreased 65%
NCT03594747 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.
  2. bPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tislelizumab

PFS 7.6 vs 5.5 Paclitaxel + Carboplatin months
time to event · months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 5 more results
7.6 vs 5.5 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
7.7 vs 5.5 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
9.6 vs 5.5 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
9.6 vs 5.5 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
9.8 vs 5.5 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 26.1 vs 19.4 Paclitaxel + Carboplatin months
time to event · months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
23.3 vs 19.4 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
Duration of Response 8.4 vs 4.3 Paclitaxel + Carboplatin months
time to event · months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 3 more results
8.6 vs 4.3 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
10.6 vs 4.8 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
8.8 vs 4.8 Paclitaxel + Carboplatin months
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-LC13 Chest Pain 0.4 score @ 15wk
absolute change · score
No placebo or comparator arm
Chest pain
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.4 score @ 15wk
Chest pain
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ LC13 Cough -7 score @ 15wk
absolute change · score
No placebo or comparator arm
Coughing
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
-0.4 score @ 15wk
Coughing
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 GHS 2.4 score @ 15wk
absolute change · score
No placebo or comparator arm
NCT03594747 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
3.3 score @ 15wk
NCT03594747 · Phase 3 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pembrolizumab berahyaluronidase alfa's landscape · Tislelizumab's landscape